AVTR vs. JNJ: Avantor vs. Johnson & Johnson Stock Comparison
How do Avantor (AVTR) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while JNJ is classified in Pharmaceuticals.
| Profile Item | AVTR | JNJ |
|---|---|---|
| Name | Avantor, Inc. | Johnson & Johnson |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.48 billion USD | 664.95 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | May 17, 2019 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | JNJ |
|---|---|---|
| Total Return (1Y) | 36.41% | 53.82% |
| Total Return (3Y, Annualized) | -5.02% | 27.51% |
| Total Return (5Y, Annualized) | -16.62% | 14.71% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | JNJ |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 21.23% |
| Beta (5Y) | 0.94 | 0.21 |
| Max Drawdown (5Y) | -82.42% | -18.41% |
| Avg. Volume (3M) | 8.56M | 6.93M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | JNJ |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 2.33 |
| Sortino Ratio (1Y) | 1.17 | 3.66 |
Profitability
ROE (TTM)
Johnson & Johnson (JNJ) at 20.02% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for JNJ.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.02%
- Max
- 109.18%
- JNJ
- 20.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Avantor (AVTR) at 5.08% and Johnson & Johnson (JNJ) at 16.20% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.20%
- Max
- 18.05%
- JNJ
- 16.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Johnson & Johnson (JNJ) at 25.74% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.74%
- Max
- 83.12%
- JNJ
- 25.74%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | JNJ |
|---|---|---|
| ROE (TTM) | 5.91% | 20.02% |
| ROA (TTM) | 2.83% | 8.46% |
| Net Margin (TTM) | 5.08% | 16.20% |
| Operating Margin (TTM) | 8.19% | 25.74% |
| Gross Margin (TTM) | 31.59% | 67.78% |
Growth
Revenue Growth
Johnson & Johnson (JNJ) at 6.05% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while Avantor (AVTR) at -175.00% is in the bottom quartile, showing a clear gap in earnings momentum.
Growth Metrics
| Metric | AVTR | JNJ |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 6.05% |
| Revenue Growth (3Y CAGR) | -4.46% | 5.60% |
| EPS Growth (YoY) | -175.00% | 90.50% |
| EPS Growth (3Y CAGR) | -- | 17.90% |
Financial Strength
Current Ratio (MRQ)
Both Avantor (AVTR) at 1.89 and Johnson & Johnson (JNJ) at 1.02 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.02
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JNJ
- 1.02
- Min
- 0.10
Debt / Equity (MRQ)
Both Avantor (AVTR) at 0.63 and Johnson & Johnson (JNJ) at 0.55 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.55
- Max
- 1.42
- Q3
- 0.65
- JNJ
- 0.55
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | JNJ |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 1.02 |
| Debt / Equity (MRQ) | 0.63 | 0.55 |
| Net Debt / EBITDA | 3.40 | 0.79 |
Dividends
Dividend Yield (TTM)
Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94%
- JNJ
- 1.94%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Avantor (AVTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
80.12%
- JNJ
- 80.12%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | JNJ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.94% |
| Dividend Payout Ratio (TTM) | 0.00% | 80.12% |
Valuation
P/E Ratio (TTM)
Both Avantor (AVTR) at 30.94 and Johnson & Johnson (JNJ) at 41.92 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.92
- Max
- 85.34
- Q3
- 43.46
- JNJ
- 41.92
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Johnson & Johnson (JNJ) at 6.69 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JNJ
- 6.69
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Avantor (AVTR) at 1.80 is valued about in line with its industry on P/B ratio, while Johnson & Johnson (JNJ) at 8.16 carries an above-peer premium to book — JNJ is pricier on assets.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
JNJ
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 13.53
- JNJ
- 8.16
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | JNJ |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 41.92 |
| P/S Ratio (TTM) | 1.58 | 6.69 |
| P/B Ratio (MRQ) | 1.80 | 8.16 |
| Free Cash Flow Yield (TTM) | 4.21% | 2.78% |